|
| n (%) |
| Male gender | 55 (52.4) |
| Age, y* | 62.3 ± 12.0 |
| Employed fulltime or part-time | 38 (36.2) |
| Education |
|
| ≤12 years | 70 (66.7) |
| Living with family or other adults | 99 (94.3) |
| Cancer type |
|
| Breast cancer | 35 (33.3) |
| Colorectal cancer | 30 (28.6) |
| Hepatocellular carcinoma | 31 (29.5) |
| Renal cell carcinoma | 9 (8.6) |
| ECOG performance status |
|
| 0 | 81 (77.1) |
| 1 | 23 (21.9) |
| 2 | 1 (1.0) |
| Anti-cancer agents |
|
| Capecitabine | 65 (61.9) |
| Sorafenib | 31 (29.5) |
| Sunitinib | 9 (8.6) |
| Time since start of treatment with relevant drug, month* | 4.6 ± 5.7 |
| CTCAE grade of HFS |
|
| Grade 1 | 67 (63.8) |
| Grade 2 | 36 (34.3) |
| Grade 3 | 2 (1.9) |